Drugs / CD19-BAFF Targeted CAR T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06346912 | May 2024 → May 2027 expected | B-cell acute lymphoblastic leukemia | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT06279923 | Apr 2024 → Feb 2027 expected | autoimmune disease | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-BAFF Targeted CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06279923 ↗ |
| Modality | Cell therapy | “CD19-BAFF CAR-T cell therapy” NCT06279923 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06279923 ↗ |
| Target | CD19 | “Targeting CD19-BAFF CAR-T Cells” NCT06279923 ↗ |